The effect of semelil (angipars？) on bone resorption and bone formation markers in type 2 diabetic patients

In this randomized, double- blind clinical trial, 61 diabetic patients were included. The subjects were randomly divided into intervention and control groups. Subjects of intervention group received 100？mg of Angipars？ twice a day. Laboratory tests including bone resorption and bone formation markers were performed at baseline and after 3？months.31 patients in study group and 30 patients in control group finished the study. The mean age of the study population and the mean disease duration was respectively 51.8？±？6.2 and 7.5？±？4.7？years with no significant differences between intervention and control patients. No statistically significant differences between patients and controls were observed in pyridinoline, osteocalcin, urine calcium, bone alkaline phosphatase and tumor necrosis factor (TNF-α). Only urine creatinine level significantly changed between two groups after 3？month of treatment (p-value: 0.029)In conclusion, the findings of this study indicate that Semelil (Angipars？) had no beneficial or harmful effects on bone. It might be other effects of this new component on bone turnover process which need more studies and more time to be discovered.Diabetes mellitus affects skeletal system and bone metabolism through multiple pathways and it has been recognized as a major risk factor for osteoporosis [1]. Besides, osteoporosis is the most prevalent metabolic bone disease, which dramatically decreases the quality of life and increase financial burden on diabetic patients [2,3].The relationship between diabetes and osteoporosis has been the main subject of many researches. Several mechanisms have been proposed for diabetes-related osteoporosis. Clinical trials uniformly support the fact that new bone formation and bone quality, are altered in both types of diabetes. Bone quality changes may be affected by micro vascular events common in diabetes [4,5]. Poor glycemic control can induce hypercalciuria which has been considered a potential risk factor for osteoporosi